RADIOTHERAPY IN MANAGEMENT OF BRCA-POSITIVE OVARIAN CANCER
https://doi.org/10.21294/1814-4861-2017-16-4-103-107
Abstract
Cancer cells with the loss of BRCA 1 or BRCA 2 function are unable to repair DNA double-strand breaks and demonstrate the increased sensitivity to various DNA-damaging agents. We aimed to describe successful treatment outcomes in two patients with BRCA1-associated ovarian cancer, who showed a complete clinical response to radiotherapy in combination with platinum-based chemotherapy. The progression-free survival was 11 months in one case and 8 months in another case.
About the Authors
T. V. Gorodnova
N.N. Petrov Research Institute of Oncology, Saint-Petersburg.
Russian Federation
Russian Federation
Gorodnova Tatiana V., MD, PhD, Research Fellow, Department of Gynecological Oncology, N.N. Petrov Research Institute of Oncology.
68, Leningradskaya Street, 197758-Saint-Petersburg, Russia.
S. B. Baranov
N.N. Petrov Research Institute of Oncology, Saint-Petersburg.
Russian Federation
Russian Federation
Baranov Sergey B., MD, PhD, Research Fellow, Department of Radiation Therapy, N.N. Petrov Research Institute of Oncology.
68, Leningradskaya Street, 197758-Saint-Petersburg, Russia.
L. N. Shevkunov
N.N. Petrov Research Institute of Oncology, Saint-Petersburg.
Russian Federation
Russian Federation
Shevkunov Lev N., MD, PhD, Radiologist, Diagnostic Imaging Department, N.N. Petrov Research Institute of Oncology.
68, Leningradskaya Street, 197758-Saint-Petersburg, Russia.
S. A. Tyatkov
N.N. Petrov Research Institute of Oncology, Saint-Petersburg.
Russian Federation
Russian Federation
Tyatkov Stanislav A., MD, Radiologist, Diagnostic Imaging Department, N.N. Petrov Research Institute of Oncology.
68, Leningradskaya Street, 197758-Saint-Petersburg, Russia.
A. P. Sokolenko
N.N. Petrov Research Institute of Oncology, Saint-Petersburg.
Russian Federation
Russian Federation
Sokolenko Anna P., MD, PhD, Research Fellow, Laboratory of Molecular Oncology, N.N. Petrov Research Institute of Oncology.
68, Leningradskaya Street, 197758-Saint-Petersburg, Russia.
C. B. Kotiv
N.N. Petrov Research Institute of Oncology, Saint-Petersburg.
Russian Federation
Russian Federation
Kotiv Christina B., Postgraduate, Department of Gynecological Oncology, N.N. Petrov Research Institute of Oncology.
68, Leningradskaya Street, 197758-Saint-Petersburg, Russia.
E. N. Imyanitov
N.N. Petrov Research Institute of Oncology, Saint-Petersburg.
Russian Federation
Russian Federation
Imyanitov Evgeny N., MD, PhD, Professor, Head of Laboratory of Molecular Oncology, N.N. Petrov Research Institute of Oncology.
68, Leningradskaya Street, 197758-Saint-Petersburg, Russia.
I. V. Berlev
N.N. Petrov Research Institute of Oncology, Saint-Petersburg.
Russian Federation
Russian Federation
Berlev Igor V., MD, PhD, Professor, Head of Gynecological Oncology Department, N.N. Petrov Research Institute of Oncology.
68, Leningradskaya Street, 197758-Saint-Petersburg, Russia.
References
1. Dembo A.J. Epithelial ovarian cancer: the role of radiotherapy. Int J Radiat Oncol Biol Phys. 1992; 22 (5): 835–845.
2. Kennedy R.D., Quinn J.E., Mullan P.B., Johnston P.G., Harkin D.P. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst. 2004; 96 (22): 1659–1668.
3. Sigurdsson K. Advanced stage III ovarian carcinoma. Prospective randomized trials comparing radiotherapy and chemotherapy. Acta Obstet. Gynaecol. 1986; 65: 65–67.
4. Gorodnova T.V., Maximov S.Ya., Guseinov К.D. Imyanitov Е.N. Assessment of the clinical efficacy of platinum-based chemotherapy in patients with BRCA-mutated ovarian cancer. Problems in Oncology. 2014; 3: 339–34. [in Russian]
5. Gorodnova T.V., Sokolenko A.P., Ivantsov A.O., Iyevleva A.G., Suspitsin E.N., Aleksakhina S.N., Yanus G.A., Togo A.V., Maximov S.Y., Imyanitov E.N. High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation. Cancer Lett. 2015; 369 (2): 363–367. doi: 10.1016/j.canlet.2015.08.028.
6. Moiseyenko V.M., Chubenko V.A., Moiseyenko F.V., Zhabina A.S., Gorodnova T.V., Komarov Y.I., Bogdanov A.A., Sokolenko A.P., Imyanitov E.N. Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation. Med Oncol. 2014; 31 (10): 199. doi: 10.1007/s12032-014-0199-x. doi: 10.1007/s12032-014-0199-x.
7. Kanaev S.V. Principles and rationale for cancer chemoradiotherapy. Practical Oncology. 2008; 1: 1–8. [in Russian]
8. Nechaeva I.D. Ovarian tumors. Medicine, 1987; 208. [in Russian]
Review
For citations:
Gorodnova T.V., Baranov S.B., Shevkunov L.N., Tyatkov S.A., Sokolenko A.P., Kotiv C.B., Imyanitov E.N., Berlev I.V. RADIOTHERAPY IN MANAGEMENT OF BRCA-POSITIVE OVARIAN CANCER. Siberian journal of oncology. 2017;16(4):103-107. (In Russ.) https://doi.org/10.21294/1814-4861-2017-16-4-103-107
Views:
1083
Email this article 
